Roche's pharma chief sees no 'short term' pricing pressure on its cancer blockbusters

Roche's Daniel O'Day

Roche ($RHHBY) pharma chief Daniel O'Day expects payers to continue piling on the pressure when it comes to drug pricing. He just doesn't expect it to affect his company's cancer stars anytime in the near future. Blockbusters Rituxan, Avastin and Herceptin won't be subject to "short term" U.S. pricing pressure since the meds treat patients with few other options, he told Reuters. Instead, he figures, it's generic drugmakers that'll take the hit. "There will be a bifurcation of the industry. There will be true innovators that are providing transformational medicines. And then there will be the generic medicines," he told the news service. More from FiercePharma

Read more on